Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
631
archived clinical trials in
Vaccines

Immunogenicity and Safety of Sci-B-Vac™ to Engerix-B® in Adults ≥ 18 Years Old and Superiority in Adults ≥ 45 Years Old.
A Phase 3 Double-Blind Randomized Controlled Trial to Compare the Immunogenicity and Safety of a Three-dose Regimen of Sci-B-Vac™ to a Three-dose Regimen of Engerix-B® in Adults (PROTECT)
Status: Enrolling
Updated:  12/31/1969
Anaheim Clinical Trials, LLC
mi
from
Anaheim, CA
Immunogenicity and Safety of Sci-B-Vac™ to Engerix-B® in Adults ≥ 18 Years Old and Superiority in Adults ≥ 45 Years Old.
A Phase 3 Double-Blind Randomized Controlled Trial to Compare the Immunogenicity and Safety of a Three-dose Regimen of Sci-B-Vac™ to a Three-dose Regimen of Engerix-B® in Adults (PROTECT)
Status: Enrolling
Updated: 12/31/1969
Anaheim Clinical Trials, LLC
mi
from
Anaheim, CA
Click here to add this to my saved trials
Immunogenicity and Safety of Sci-B-Vac™ to Engerix-B® in Adults ≥ 18 Years Old and Superiority in Adults ≥ 45 Years Old.
A Phase 3 Double-Blind Randomized Controlled Trial to Compare the Immunogenicity and Safety of a Three-dose Regimen of Sci-B-Vac™ to a Three-dose Regimen of Engerix-B® in Adults (PROTECT)
Status: Enrolling
Updated:  12/31/1969
Avail Clinical Research
mi
from
DeLand, FL
Immunogenicity and Safety of Sci-B-Vac™ to Engerix-B® in Adults ≥ 18 Years Old and Superiority in Adults ≥ 45 Years Old.
A Phase 3 Double-Blind Randomized Controlled Trial to Compare the Immunogenicity and Safety of a Three-dose Regimen of Sci-B-Vac™ to a Three-dose Regimen of Engerix-B® in Adults (PROTECT)
Status: Enrolling
Updated: 12/31/1969
Avail Clinical Research
mi
from
DeLand, FL
Click here to add this to my saved trials
Immunogenicity and Safety of Sci-B-Vac™ to Engerix-B® in Adults ≥ 18 Years Old and Superiority in Adults ≥ 45 Years Old.
A Phase 3 Double-Blind Randomized Controlled Trial to Compare the Immunogenicity and Safety of a Three-dose Regimen of Sci-B-Vac™ to a Three-dose Regimen of Engerix-B® in Adults (PROTECT)
Status: Enrolling
Updated:  12/31/1969
Suncoast Research Group, LLC
mi
from
Miami, FL
Immunogenicity and Safety of Sci-B-Vac™ to Engerix-B® in Adults ≥ 18 Years Old and Superiority in Adults ≥ 45 Years Old.
A Phase 3 Double-Blind Randomized Controlled Trial to Compare the Immunogenicity and Safety of a Three-dose Regimen of Sci-B-Vac™ to a Three-dose Regimen of Engerix-B® in Adults (PROTECT)
Status: Enrolling
Updated: 12/31/1969
Suncoast Research Group, LLC
mi
from
Miami, FL
Click here to add this to my saved trials
Immunogenicity and Safety of Sci-B-Vac™ to Engerix-B® in Adults ≥ 18 Years Old and Superiority in Adults ≥ 45 Years Old.
A Phase 3 Double-Blind Randomized Controlled Trial to Compare the Immunogenicity and Safety of a Three-dose Regimen of Sci-B-Vac™ to a Three-dose Regimen of Engerix-B® in Adults (PROTECT)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Atlanta
mi
from
Atlanta, GA
Immunogenicity and Safety of Sci-B-Vac™ to Engerix-B® in Adults ≥ 18 Years Old and Superiority in Adults ≥ 45 Years Old.
A Phase 3 Double-Blind Randomized Controlled Trial to Compare the Immunogenicity and Safety of a Three-dose Regimen of Sci-B-Vac™ to a Three-dose Regimen of Engerix-B® in Adults (PROTECT)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Atlanta
mi
from
Atlanta, GA
Click here to add this to my saved trials
Immunogenicity and Safety of Sci-B-Vac™ to Engerix-B® in Adults ≥ 18 Years Old and Superiority in Adults ≥ 45 Years Old.
A Phase 3 Double-Blind Randomized Controlled Trial to Compare the Immunogenicity and Safety of a Three-dose Regimen of Sci-B-Vac™ to a Three-dose Regimen of Engerix-B® in Adults (PROTECT)
Status: Enrolling
Updated:  12/31/1969
Advanced Clinical Research
mi
from
Boise, ID
Immunogenicity and Safety of Sci-B-Vac™ to Engerix-B® in Adults ≥ 18 Years Old and Superiority in Adults ≥ 45 Years Old.
A Phase 3 Double-Blind Randomized Controlled Trial to Compare the Immunogenicity and Safety of a Three-dose Regimen of Sci-B-Vac™ to a Three-dose Regimen of Engerix-B® in Adults (PROTECT)
Status: Enrolling
Updated: 12/31/1969
Advanced Clinical Research
mi
from
Boise, ID
Click here to add this to my saved trials
Immunogenicity and Safety of Sci-B-Vac™ to Engerix-B® in Adults ≥ 18 Years Old and Superiority in Adults ≥ 45 Years Old.
A Phase 3 Double-Blind Randomized Controlled Trial to Compare the Immunogenicity and Safety of a Three-dose Regimen of Sci-B-Vac™ to a Three-dose Regimen of Engerix-B® in Adults (PROTECT)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Center of Nevada, LLC
mi
from
Las Vegas, NV
Immunogenicity and Safety of Sci-B-Vac™ to Engerix-B® in Adults ≥ 18 Years Old and Superiority in Adults ≥ 45 Years Old.
A Phase 3 Double-Blind Randomized Controlled Trial to Compare the Immunogenicity and Safety of a Three-dose Regimen of Sci-B-Vac™ to a Three-dose Regimen of Engerix-B® in Adults (PROTECT)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Center of Nevada, LLC
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Immunogenicity and Safety of Sci-B-Vac™ to Engerix-B® in Adults ≥ 18 Years Old and Superiority in Adults ≥ 45 Years Old.
A Phase 3 Double-Blind Randomized Controlled Trial to Compare the Immunogenicity and Safety of a Three-dose Regimen of Sci-B-Vac™ to a Three-dose Regimen of Engerix-B® in Adults (PROTECT)
Status: Enrolling
Updated:  12/31/1969
Rapid Medical Research, Inc.
mi
from
Cleveland, OH
Immunogenicity and Safety of Sci-B-Vac™ to Engerix-B® in Adults ≥ 18 Years Old and Superiority in Adults ≥ 45 Years Old.
A Phase 3 Double-Blind Randomized Controlled Trial to Compare the Immunogenicity and Safety of a Three-dose Regimen of Sci-B-Vac™ to a Three-dose Regimen of Engerix-B® in Adults (PROTECT)
Status: Enrolling
Updated: 12/31/1969
Rapid Medical Research, Inc.
mi
from
Cleveland, OH
Click here to add this to my saved trials
Immunogenicity and Safety of Sci-B-Vac™ to Engerix-B® in Adults ≥ 18 Years Old and Superiority in Adults ≥ 45 Years Old.
A Phase 3 Double-Blind Randomized Controlled Trial to Compare the Immunogenicity and Safety of a Three-dose Regimen of Sci-B-Vac™ to a Three-dose Regimen of Engerix-B® in Adults (PROTECT)
Status: Enrolling
Updated:  12/31/1969
Lynn Health Science Institute
mi
from
Oklahoma City, OK
Immunogenicity and Safety of Sci-B-Vac™ to Engerix-B® in Adults ≥ 18 Years Old and Superiority in Adults ≥ 45 Years Old.
A Phase 3 Double-Blind Randomized Controlled Trial to Compare the Immunogenicity and Safety of a Three-dose Regimen of Sci-B-Vac™ to a Three-dose Regimen of Engerix-B® in Adults (PROTECT)
Status: Enrolling
Updated: 12/31/1969
Lynn Health Science Institute
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Immunogenicity and Safety of Sci-B-Vac™ to Engerix-B® in Adults ≥ 18 Years Old and Superiority in Adults ≥ 45 Years Old.
A Phase 3 Double-Blind Randomized Controlled Trial to Compare the Immunogenicity and Safety of a Three-dose Regimen of Sci-B-Vac™ to a Three-dose Regimen of Engerix-B® in Adults (PROTECT)
Status: Enrolling
Updated:  12/31/1969
Advanced Clinical Research
mi
from
Salt Lake City, UT
Immunogenicity and Safety of Sci-B-Vac™ to Engerix-B® in Adults ≥ 18 Years Old and Superiority in Adults ≥ 45 Years Old.
A Phase 3 Double-Blind Randomized Controlled Trial to Compare the Immunogenicity and Safety of a Three-dose Regimen of Sci-B-Vac™ to a Three-dose Regimen of Engerix-B® in Adults (PROTECT)
Status: Enrolling
Updated: 12/31/1969
Advanced Clinical Research
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Immunogenicity and Safety of Sci-B-Vac™ to Engerix-B® in Adults ≥ 18 Years Old and Superiority in Adults ≥ 45 Years Old.
A Phase 3 Double-Blind Randomized Controlled Trial to Compare the Immunogenicity and Safety of a Three-dose Regimen of Sci-B-Vac™ to a Three-dose Regimen of Engerix-B® in Adults (PROTECT)
Status: Enrolling
Updated:  12/31/1969
Universitair Ziekenhuis Gent
mi
from
Gent,
Immunogenicity and Safety of Sci-B-Vac™ to Engerix-B® in Adults ≥ 18 Years Old and Superiority in Adults ≥ 45 Years Old.
A Phase 3 Double-Blind Randomized Controlled Trial to Compare the Immunogenicity and Safety of a Three-dose Regimen of Sci-B-Vac™ to a Three-dose Regimen of Engerix-B® in Adults (PROTECT)
Status: Enrolling
Updated: 12/31/1969
Universitair Ziekenhuis Gent
mi
from
Gent,
Click here to add this to my saved trials
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)
Status: Enrolling
Updated:  12/31/1969
Accel Research Sites
mi
from
Birmingham, AL
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)
Status: Enrolling
Updated: 12/31/1969
Accel Research Sites
mi
from
Birmingham, AL
Click here to add this to my saved trials
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)
Status: Enrolling
Updated:  12/31/1969
Anaheim Clinical Trials, LLC
mi
from
Anaheim, CA
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)
Status: Enrolling
Updated: 12/31/1969
Anaheim Clinical Trials, LLC
mi
from
Anaheim, CA
Click here to add this to my saved trials
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)
Status: Enrolling
Updated:  12/31/1969
Avail Clinical Research
mi
from
DeLand, FL
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)
Status: Enrolling
Updated: 12/31/1969
Avail Clinical Research
mi
from
DeLand, FL
Click here to add this to my saved trials
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)
Status: Enrolling
Updated:  12/31/1969
Suncoast Research Group, LLC
mi
from
Miami, FL
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)
Status: Enrolling
Updated: 12/31/1969
Suncoast Research Group, LLC
mi
from
Miami, FL
Click here to add this to my saved trials
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Altanta
mi
from
Atlanta, GA
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Altanta
mi
from
Atlanta, GA
Click here to add this to my saved trials
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)
Status: Enrolling
Updated:  12/31/1969
Advanced Clinical Research (ACR)
mi
from
Boise, ID
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)
Status: Enrolling
Updated: 12/31/1969
Advanced Clinical Research (ACR)
mi
from
Boise, ID
Click here to add this to my saved trials
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Center of Nevada, LLC
mi
from
Las Vegas, NV
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Center of Nevada, LLC
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)
Status: Enrolling
Updated:  12/31/1969
Rapid Medical Research, Inc.
mi
from
Cleveland, OH
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)
Status: Enrolling
Updated: 12/31/1969
Rapid Medical Research, Inc.
mi
from
Cleveland, OH
Click here to add this to my saved trials
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)
Status: Enrolling
Updated:  12/31/1969
Lynn Health Science Institute
mi
from
Oklahoma City, OK
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)
Status: Enrolling
Updated: 12/31/1969
Lynn Health Science Institute
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)
Status: Enrolling
Updated:  12/31/1969
Advanced Clinical Research (ACR)
mi
from
Salt Lake City, UT
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)
Status: Enrolling
Updated: 12/31/1969
Advanced Clinical Research (ACR)
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)
Status: Enrolling
Updated:  12/31/1969
Universitair Ziekenhuis Gent
mi
from
Gent,
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)
Status: Enrolling
Updated: 12/31/1969
Universitair Ziekenhuis Gent
mi
from
Gent,
Click here to add this to my saved trials
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Consortium Arizona
mi
from
Tempe, AZ
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Consortium Arizona
mi
from
Tempe, AZ
Click here to add this to my saved trials
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)
Status: Enrolling
Updated:  12/31/1969
Ruane Clinical Research Group
mi
from
Los Angeles, CA
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)
Status: Enrolling
Updated: 12/31/1969
Ruane Clinical Research Group
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)
Status: Enrolling
Updated:  12/31/1969
CareOne Research
mi
from
North Hollywood, CA
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)
Status: Enrolling
Updated: 12/31/1969
CareOne Research
mi
from
North Hollywood, CA
Click here to add this to my saved trials
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)
Status: Enrolling
Updated:  12/31/1969
Montana Medical Research
mi
from
Missoula, MT
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)
Status: Enrolling
Updated: 12/31/1969
Montana Medical Research
mi
from
Missoula, MT
Click here to add this to my saved trials
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)
Status: Enrolling
Updated:  12/31/1969
Aventiv Research
mi
from
Columbus, OH
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)
Status: Enrolling
Updated: 12/31/1969
Aventiv Research
mi
from
Columbus, OH
Click here to add this to my saved trials
Effectiveness of a Vaccination Program in the Community Ob/Gyn Setting
Effectiveness of a Vaccination Program in the Community Ob/Gyn Setting
Status: Enrolling
Updated:  1/23/2009
DWHA
mi
from
Durham, NC
Effectiveness of a Vaccination Program in the Community Ob/Gyn Setting
Effectiveness of a Vaccination Program in the Community Ob/Gyn Setting
Status: Enrolling
Updated: 1/23/2009
DWHA
mi
from
Durham, NC
Click here to add this to my saved trials
Low Dose Radiation Therapy as Chemosensitizer in GI/ Ovarian Tumors
GCC 0319: A Phase I/II Study of Low-Dose Upper Abdominal Radiation Therapy (UART) or Whole (W) ART as Chemosensitizer in Patients With Locally Advanced or Metastatic Tumors of the Gastrointestinal Tract or Ovary
Status: Enrolling
Updated:  6/29/2009
University of Maryland & Baltimore VA medical centre
mi
from
Baltimore, MD
Low Dose Radiation Therapy as Chemosensitizer in GI/ Ovarian Tumors
GCC 0319: A Phase I/II Study of Low-Dose Upper Abdominal Radiation Therapy (UART) or Whole (W) ART as Chemosensitizer in Patients With Locally Advanced or Metastatic Tumors of the Gastrointestinal Tract or Ovary
Status: Enrolling
Updated: 6/29/2009
University of Maryland & Baltimore VA medical centre
mi
from
Baltimore, MD
Click here to add this to my saved trials
Effectiveness of SMS (Short Message Service) Text Messaging in Increasing Adherence to Gardasil
A Randomized, Controlled Trial to Compare the Effectiveness of SMS Text Message Reminders Compared to Usual Care to Increase Adherence to the Gardasil Vaccine Dosing Schedule (GCC 1063GCC).
Status: Enrolling
Updated:  1/12/2011
Redwood Clinic
mi
from
Baltimore, MD
Effectiveness of SMS (Short Message Service) Text Messaging in Increasing Adherence to Gardasil
A Randomized, Controlled Trial to Compare the Effectiveness of SMS Text Message Reminders Compared to Usual Care to Increase Adherence to the Gardasil Vaccine Dosing Schedule (GCC 1063GCC).
Status: Enrolling
Updated: 1/12/2011
Redwood Clinic
mi
from
Baltimore, MD
Click here to add this to my saved trials
Effectiveness of SMS (Short Message Service) Text Messaging in Increasing Adherence to Gardasil
A Randomized, Controlled Trial to Compare the Effectiveness of SMS Text Message Reminders Compared to Usual Care to Increase Adherence to the Gardasil Vaccine Dosing Schedule (GCC 1063GCC).
Status: Enrolling
Updated:  1/12/2011
Western-Penn Center
mi
from
Baltimore, MD
Effectiveness of SMS (Short Message Service) Text Messaging in Increasing Adherence to Gardasil
A Randomized, Controlled Trial to Compare the Effectiveness of SMS Text Message Reminders Compared to Usual Care to Increase Adherence to the Gardasil Vaccine Dosing Schedule (GCC 1063GCC).
Status: Enrolling
Updated: 1/12/2011
Western-Penn Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Phase I Safety Trial of Streptococcus Pneumoniae Whole Cell Vaccine (SPWCV) + Alum in Healthy Adults
A Phase 1 Randomized, Double-Blind, Dose-Escalation Study to Assess the Safety, Tolerability and Immunogenicity of Inactivated Streptococcus Pneumoniae Whole Cell Vaccine Formulated With Alum (SPWCV+Alum) in Healthy Adults
Status: Enrolling
Updated:  3/14/2012
Comprehensive Clinical Development
mi
from
Tacoma, WA
Phase I Safety Trial of Streptococcus Pneumoniae Whole Cell Vaccine (SPWCV) + Alum in Healthy Adults
A Phase 1 Randomized, Double-Blind, Dose-Escalation Study to Assess the Safety, Tolerability and Immunogenicity of Inactivated Streptococcus Pneumoniae Whole Cell Vaccine Formulated With Alum (SPWCV+Alum) in Healthy Adults
Status: Enrolling
Updated: 3/14/2012
Comprehensive Clinical Development
mi
from
Tacoma, WA
Click here to add this to my saved trials
MAS-1 Adjuvanted Compared to Unadjuvanted Influenza Vaccines in the Elderly
MAS-1 Adjuvanted Compared to Unadjuvanted Influenza Vaccines in the Elderly
Status: Enrolling
Updated:  6/26/2012
VA Palo Alto Health Care System, Palo Alto, CA
mi
from
Palo Alto, CA
MAS-1 Adjuvanted Compared to Unadjuvanted Influenza Vaccines in the Elderly
MAS-1 Adjuvanted Compared to Unadjuvanted Influenza Vaccines in the Elderly
Status: Enrolling
Updated: 6/26/2012
VA Palo Alto Health Care System, Palo Alto, CA
mi
from
Palo Alto, CA
Click here to add this to my saved trials
MAS-1 Adjuvanted Compared to Unadjuvanted Influenza Vaccines in the Elderly
MAS-1 Adjuvanted Compared to Unadjuvanted Influenza Vaccines in the Elderly
Status: Enrolling
Updated:  6/26/2012
Iowa City VA Health Care System, Iowa City, IA
mi
from
Iowa City, IA
MAS-1 Adjuvanted Compared to Unadjuvanted Influenza Vaccines in the Elderly
MAS-1 Adjuvanted Compared to Unadjuvanted Influenza Vaccines in the Elderly
Status: Enrolling
Updated: 6/26/2012
Iowa City VA Health Care System, Iowa City, IA
mi
from
Iowa City, IA
Click here to add this to my saved trials
MAS-1 Adjuvanted Compared to Unadjuvanted Influenza Vaccines in the Elderly
MAS-1 Adjuvanted Compared to Unadjuvanted Influenza Vaccines in the Elderly
Status: Enrolling
Updated:  6/26/2012
Minneapolis VA Health Care System, Minneapolis, MN
mi
from
Minneapolis, MN
MAS-1 Adjuvanted Compared to Unadjuvanted Influenza Vaccines in the Elderly
MAS-1 Adjuvanted Compared to Unadjuvanted Influenza Vaccines in the Elderly
Status: Enrolling
Updated: 6/26/2012
Minneapolis VA Health Care System, Minneapolis, MN
mi
from
Minneapolis, MN
Click here to add this to my saved trials
MAS-1 Adjuvanted Compared to Unadjuvanted Influenza Vaccines in the Elderly
MAS-1 Adjuvanted Compared to Unadjuvanted Influenza Vaccines in the Elderly
Status: Enrolling
Updated:  6/26/2012
St. Louis VA Medical Center John Cochran Division, St. Louis, MO
mi
from
St Louis, MO
MAS-1 Adjuvanted Compared to Unadjuvanted Influenza Vaccines in the Elderly
MAS-1 Adjuvanted Compared to Unadjuvanted Influenza Vaccines in the Elderly
Status: Enrolling
Updated: 6/26/2012
St. Louis VA Medical Center John Cochran Division, St. Louis, MO
mi
from
St Louis, MO
Click here to add this to my saved trials
Girls OnGuard: HPV Vaccination Uptake Among African American Adolescent Females
Overcoming Barriers to Vaccination With GARDASIL in Underserved Girls and Adolescents
Status: Enrolling
Updated:  8/7/2012
Fulton County Department of Health and Wellness
mi
from
Atlanta, GA
Girls OnGuard: HPV Vaccination Uptake Among African American Adolescent Females
Overcoming Barriers to Vaccination With GARDASIL in Underserved Girls and Adolescents
Status: Enrolling
Updated: 8/7/2012
Fulton County Department of Health and Wellness
mi
from
Atlanta, GA
Click here to add this to my saved trials
Girls OnGuard: HPV Vaccination Uptake Among African American Adolescent Females
Overcoming Barriers to Vaccination With GARDASIL in Underserved Girls and Adolescents
Status: Enrolling
Updated:  8/7/2012
DeKalb County Health Department
mi
from
Decatur, GA
Girls OnGuard: HPV Vaccination Uptake Among African American Adolescent Females
Overcoming Barriers to Vaccination With GARDASIL in Underserved Girls and Adolescents
Status: Enrolling
Updated: 8/7/2012
DeKalb County Health Department
mi
from
Decatur, GA
Click here to add this to my saved trials
Text Message Reminder-Recalls For Early Childhood Vaccination
Text 4 Health-Kids: Text Message Reminder-Recalls For Early Childhood Vaccination
Status: Enrolling
Updated:  2/11/2013
Columbia University Medical Center
mi
from
New York, NY
Text Message Reminder-Recalls For Early Childhood Vaccination
Text 4 Health-Kids: Text Message Reminder-Recalls For Early Childhood Vaccination
Status: Enrolling
Updated: 2/11/2013
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Children With Sickle Cell Disease
A Phase 3, Open-Label, Single-Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine in Children With Sickle Cell Disease Previously Immunized With 23vPS Vaccine
Status: Enrolling
Updated:  3/12/2013
Pfizer Investigational Site
mi
from
Alabaster, AL
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Children With Sickle Cell Disease
A Phase 3, Open-Label, Single-Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine in Children With Sickle Cell Disease Previously Immunized With 23vPS Vaccine
Status: Enrolling
Updated: 3/12/2013
Pfizer Investigational Site
mi
from
Alabaster, AL
Click here to add this to my saved trials
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Children With Sickle Cell Disease
A Phase 3, Open-Label, Single-Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine in Children With Sickle Cell Disease Previously Immunized With 23vPS Vaccine
Status: Enrolling
Updated:  3/12/2013
Pfizer Investigational Site
mi
from
Ashland, KY
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Children With Sickle Cell Disease
A Phase 3, Open-Label, Single-Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine in Children With Sickle Cell Disease Previously Immunized With 23vPS Vaccine
Status: Enrolling
Updated: 3/12/2013
Pfizer Investigational Site
mi
from
Ashland, KY
Click here to add this to my saved trials
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Children With Sickle Cell Disease
A Phase 3, Open-Label, Single-Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine in Children With Sickle Cell Disease Previously Immunized With 23vPS Vaccine
Status: Enrolling
Updated:  3/12/2013
Pfizer Investigational Site
mi
from
Rochester, NY
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Children With Sickle Cell Disease
A Phase 3, Open-Label, Single-Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine in Children With Sickle Cell Disease Previously Immunized With 23vPS Vaccine
Status: Enrolling
Updated: 3/12/2013
Pfizer Investigational Site
mi
from
Rochester, NY
Click here to add this to my saved trials
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Children With Sickle Cell Disease
A Phase 3, Open-Label, Single-Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine in Children With Sickle Cell Disease Previously Immunized With 23vPS Vaccine
Status: Enrolling
Updated:  3/12/2013
Pfizer Investigational Site
mi
from
Bristol, TN
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Children With Sickle Cell Disease
A Phase 3, Open-Label, Single-Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine in Children With Sickle Cell Disease Previously Immunized With 23vPS Vaccine
Status: Enrolling
Updated: 3/12/2013
Pfizer Investigational Site
mi
from
Bristol, TN
Click here to add this to my saved trials
Post-marketing Safety Study of Autoimmune Diseases Following Cervarix® Vaccination
Post-marketing Safety Study of Autoimmune Diseases Following Cervarix® Vaccination in Females Aged 9-25 Years in the US
Status: Enrolling
Updated:  4/17/2014
GSK Investigational Site
mi
from
Wilmington, DE
Post-marketing Safety Study of Autoimmune Diseases Following Cervarix® Vaccination
Post-marketing Safety Study of Autoimmune Diseases Following Cervarix® Vaccination in Females Aged 9-25 Years in the US
Status: Enrolling
Updated: 4/17/2014
GSK Investigational Site
mi
from
Wilmington, DE
Click here to add this to my saved trials
Permission to Collect Blood Over Time for Research
Predicting DVT Risk in GI Cancer Patients Using Plasma Biomarkers
Status: Enrolling
Updated:  5/20/2014
Stanford University School of Medicine
mi
from
Stanford, CA
Permission to Collect Blood Over Time for Research
Predicting DVT Risk in GI Cancer Patients Using Plasma Biomarkers
Status: Enrolling
Updated: 5/20/2014
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years
A Phase 3, Randomized, Active-controlled, Observer-blinded Trial To Assess The Lot Consistency, Safety, Tolerability, And Immunogenicity Of A Meningococcal Serogroup B Bivalent Rlp2086 Vaccine In Healthy Subjects Aged >/=10 To <19 Years
Status: Enrolling
Updated:  3/13/2015
Alabama Clinical Therapeutics, Llc
mi
from
Birmingham, AL
A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years
A Phase 3, Randomized, Active-controlled, Observer-blinded Trial To Assess The Lot Consistency, Safety, Tolerability, And Immunogenicity Of A Meningococcal Serogroup B Bivalent Rlp2086 Vaccine In Healthy Subjects Aged >/=10 To <19 Years
Status: Enrolling
Updated: 3/13/2015
Alabama Clinical Therapeutics, Llc
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years
A Phase 3, Randomized, Active-controlled, Observer-blinded Trial To Assess The Lot Consistency, Safety, Tolerability, And Immunogenicity Of A Meningococcal Serogroup B Bivalent Rlp2086 Vaccine In Healthy Subjects Aged >/=10 To <19 Years
Status: Enrolling
Updated:  3/13/2015
Birmingham Pediatric Associates
mi
from
Birmingham, AL
A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years
A Phase 3, Randomized, Active-controlled, Observer-blinded Trial To Assess The Lot Consistency, Safety, Tolerability, And Immunogenicity Of A Meningococcal Serogroup B Bivalent Rlp2086 Vaccine In Healthy Subjects Aged >/=10 To <19 Years
Status: Enrolling
Updated: 3/13/2015
Birmingham Pediatric Associates
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years
A Phase 3, Randomized, Active-controlled, Observer-blinded Trial To Assess The Lot Consistency, Safety, Tolerability, And Immunogenicity Of A Meningococcal Serogroup B Bivalent Rlp2086 Vaccine In Healthy Subjects Aged >/=10 To <19 Years
Status: Enrolling
Updated:  3/13/2015
Southeastern Pediatrics
mi
from
Dothan, AL
A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years
A Phase 3, Randomized, Active-controlled, Observer-blinded Trial To Assess The Lot Consistency, Safety, Tolerability, And Immunogenicity Of A Meningococcal Serogroup B Bivalent Rlp2086 Vaccine In Healthy Subjects Aged >/=10 To <19 Years
Status: Enrolling
Updated: 3/13/2015
Southeastern Pediatrics
mi
from
Dothan, AL
Click here to add this to my saved trials
A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years
A Phase 3, Randomized, Active-controlled, Observer-blinded Trial To Assess The Lot Consistency, Safety, Tolerability, And Immunogenicity Of A Meningococcal Serogroup B Bivalent Rlp2086 Vaccine In Healthy Subjects Aged >/=10 To <19 Years
Status: Enrolling
Updated:  3/13/2015
Harrisburg Family Medical Center
mi
from
Harrisburg, AR
A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years
A Phase 3, Randomized, Active-controlled, Observer-blinded Trial To Assess The Lot Consistency, Safety, Tolerability, And Immunogenicity Of A Meningococcal Serogroup B Bivalent Rlp2086 Vaccine In Healthy Subjects Aged >/=10 To <19 Years
Status: Enrolling
Updated: 3/13/2015
Harrisburg Family Medical Center
mi
from
Harrisburg, AR
Click here to add this to my saved trials
A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years
A Phase 3, Randomized, Active-controlled, Observer-blinded Trial To Assess The Lot Consistency, Safety, Tolerability, And Immunogenicity Of A Meningococcal Serogroup B Bivalent Rlp2086 Vaccine In Healthy Subjects Aged >/=10 To <19 Years
Status: Enrolling
Updated:  3/13/2015
The Children'S Clinic of Jonesboro, P.A.
mi
from
Jonesboro, AR
A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years
A Phase 3, Randomized, Active-controlled, Observer-blinded Trial To Assess The Lot Consistency, Safety, Tolerability, And Immunogenicity Of A Meningococcal Serogroup B Bivalent Rlp2086 Vaccine In Healthy Subjects Aged >/=10 To <19 Years
Status: Enrolling
Updated: 3/13/2015
The Children'S Clinic of Jonesboro, P.A.
mi
from
Jonesboro, AR
Click here to add this to my saved trials
A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years
A Phase 3, Randomized, Active-controlled, Observer-blinded Trial To Assess The Lot Consistency, Safety, Tolerability, And Immunogenicity Of A Meningococcal Serogroup B Bivalent Rlp2086 Vaccine In Healthy Subjects Aged >/=10 To <19 Years
Status: Enrolling
Updated:  3/13/2015
Arkansas Pediatric Clinic
mi
from
Little Rock, AR
A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years
A Phase 3, Randomized, Active-controlled, Observer-blinded Trial To Assess The Lot Consistency, Safety, Tolerability, And Immunogenicity Of A Meningococcal Serogroup B Bivalent Rlp2086 Vaccine In Healthy Subjects Aged >/=10 To <19 Years
Status: Enrolling
Updated: 3/13/2015
Arkansas Pediatric Clinic
mi
from
Little Rock, AR
Click here to add this to my saved trials